In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

However, its low valuation could have investors wondering if now is the right time to take a chance on the business, ...

CVS Health is launching an app that will allow customers access to locked display cabinets "for easier access to merchandise, ...

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial. Madison Muller has more on Bloomberg Television.